Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 4/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 3/20 | 0.35 |
| ▸ | ILK | Q13418 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 5/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865122 | 0.76 | HTR2A (0.34) | PDE3BPDE3AHTR2AHTR2CPDGFRB | |
| SCHEMBL1662715 | 0.75 | PDE10A (0.40) | FYNAXL | |
| SCHEMBL1662957 | 0.69 | MAPT (0.33) | FYNPDE3AGRM5 | |
| SCHEMBL12019130 | 0.63 | CCNT1 (0.34) | PDE3BPDE3AHTR2AJAK2JAK1 | |
| SCHEMBL30682140 | 0.62 | HPGD (0.35) | — | |
| SCHEMBL28412458 | 0.62 | HPGD (0.35) | — | |
| SCHEMBL13313436 | 0.59 | NQO2 (0.46) | — | |
| SCHEMBL1662996 | 0.58 | TSHR (0.41) | — | |
| SCHEMBL6165212 | 0.58 | S1PR1 (0.40) | — | |
| SCHEMBL30682133 | 0.58 | AXL (0.42) | AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-08-30 | — | — | US | disclosed |
| EP-2490693-A1 | PYRAZOLO [3,4-b]PYRIDIN-4-ONE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011049722-A1 | PYRAZOLO [3,4-b] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | CDK1, CDK5, TTBK1 | FYN 300/4885PDE3B 1374/4885PDE3A 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.